Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Cstl crawled time : 12:00 save search
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.63%
H: 0.82%
C: -0.14%
first conference financial results
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
Published: 2024-04-10 (Crawled : 12:00) - biospace.com/
XYF | $3.78 0.0% 5.6K
|
Finance
|
| O: -2.11%
H: 2.96%
C: 2.15%
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.76%
H: 0.0%
C: 0.0%
year for financial
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.46%
H: 2.72%
C: 2.26%
conference
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
Published: 2023-09-25 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: -0.84%
melanoma nasdaq bell cancer impact skin
Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
Published: 2023-09-12 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.59%
H: 0.92%
C: -2.14%
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-06-20 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.14%
H: 4.3%
C: 1.69%
nasdaq grants
Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology
Published: 2023-06-05 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -22.13%
H: 0.96%
C: -34.12%
decisiondx test cell results
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
Published: 2023-05-15 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.35%
H: 3.12%
C: 2.66%
tissuecypher award test innovation
DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients
Published: 2023-04-25 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.6%
H: 0.0%
C: -3.34%
decisiondx melanoma cancer risk
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
Published: 2023-04-20 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.98%
H: 3.64%
C: 2.96%
tissuecypher management test results
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
Published: 2022-10-27 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.27%
H: 0.43%
C: -1.35%
collaboration program results cancer
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: -6.83%
decisiondx risk management test impact one results cell carcinoma
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
Published: 2022-10-19 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.66%
H: 2.68%
C: -5.23%
conference financial results
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline
Published: 2022-10-13 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -5.49%
H: 5.93%
C: 4.56%
tissuecypher risk test trial results
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
Published: 2022-10-11 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.21%
H: 1.79%
C: 0.25%
cap22 diffdx meeting diagnostic study
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
Published: 2022-10-10 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.09%
H: 1.6%
C: -8.51%
meeting skin cancer lsd
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
Published: 2022-09-23 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.6%
H: 2.01%
C: 0.2%
decisiondx melanoma integration publication study
Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
Published: 2022-09-21 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 5.36%
H: 2.4%
C: -4.98%
conference diagnostic derm
Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
Published: 2022-09-13 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -2.08%
H: 0.0%
C: -3.02%
Artificial Intelligence-powered (AI) Spatial Biology Market Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-08-30 (Crawled : 12:00) - prnewswire.com
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 1.15%
H: 1.07%
C: -1.9%
report market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.